Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L18a pseudogene 9 (RPL18AP9) is a processed pseudogene derived from the ribosomal protein L18a gene. Unlike its parent gene, RPL18A, which encodes a component of the 60S ribosomal subunit and is essential for protein synthesis, RPL18AP9 is noncoding and does not produce a functional polypeptide. As with many ribosomal protein pseudogenes, it originated from reverse-transcribed mRNA integrated into the genome. While some pseudogenes regulate their parental gene or act in microRNA pathways, there is no evidence that RPL18AP9 has any direct biological or pathological role, nor is it a therapeutic target.
None
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L18a pseudogene 9 (RPL18AP9).